Abstract
Prostate cancer (CaP) is one of the most common malignancies in men, with an increasing incidence. Despite advances in surgery, chemotherapy and radiotherapy to treat CaP, many patients unfortunately succumb to metastatic disease. The progression of CaP from primary to metastatic disease is associated with a number of molecular and genetic changes. These changes can effect the expression of specific tumor-associated antigens (TAAs) or receptors on the cell surface. Current therapeutic options for patients with metastatic hormone-refractory CaP (HRPC) are very limited. Targeting cancer surface TAAs is a developing area, and may have a promising future for control of late stage and recurrent CaP disease. This review describes some important CaP TAAs including prostate-specific membrane antigen (PSMA), MUC1, urokinase plasminogen activator and its receptor (uPA/uPAR), vascular endothelial growth factor and its receptor (VEGF/VEGFR), extracellular matrix metalloproteinase inducer (EMMPRIN/CD147), epidermal growth factor receptor (EGFR), platelet-derived growth factor and its receptor (PDGF/PDGFR) and c-kit (CD117). We summarize recent progress supporting the role of these TAAs in CaP progression and establish the potential therapeutic efficacy of TAAstargeted therapies in CaP.
Keywords: Cancer therapy, prostate cancer, tumor-associated antigen, metastasis
Current Cancer Therapy Reviews
Title: Overview of Tumor-Associated Antigens (TAAs) as Potential Therapeutic Targets for Prostate Cancer Therapy
Volume: 4 Issue: 4
Author(s): Paul J. Cozzi, John Kearsley and Yong Li
Affiliation:
Keywords: Cancer therapy, prostate cancer, tumor-associated antigen, metastasis
Abstract: Prostate cancer (CaP) is one of the most common malignancies in men, with an increasing incidence. Despite advances in surgery, chemotherapy and radiotherapy to treat CaP, many patients unfortunately succumb to metastatic disease. The progression of CaP from primary to metastatic disease is associated with a number of molecular and genetic changes. These changes can effect the expression of specific tumor-associated antigens (TAAs) or receptors on the cell surface. Current therapeutic options for patients with metastatic hormone-refractory CaP (HRPC) are very limited. Targeting cancer surface TAAs is a developing area, and may have a promising future for control of late stage and recurrent CaP disease. This review describes some important CaP TAAs including prostate-specific membrane antigen (PSMA), MUC1, urokinase plasminogen activator and its receptor (uPA/uPAR), vascular endothelial growth factor and its receptor (VEGF/VEGFR), extracellular matrix metalloproteinase inducer (EMMPRIN/CD147), epidermal growth factor receptor (EGFR), platelet-derived growth factor and its receptor (PDGF/PDGFR) and c-kit (CD117). We summarize recent progress supporting the role of these TAAs in CaP progression and establish the potential therapeutic efficacy of TAAstargeted therapies in CaP.
Export Options
About this article
Cite this article as:
Cozzi J. Paul, Kearsley John and Li Yong, Overview of Tumor-Associated Antigens (TAAs) as Potential Therapeutic Targets for Prostate Cancer Therapy, Current Cancer Therapy Reviews 2008; 4 (4) . https://dx.doi.org/10.2174/157339408786413371
DOI https://dx.doi.org/10.2174/157339408786413371 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immune Modulation by Ionizing Radiation and its Implications for Cancer Immunotherapy
Current Pharmaceutical Design Targeting Proteasomal Pathways by Dietary Curcumin for Cancer Prevention and Treatment
Current Medicinal Chemistry Efficacy and Safety of Nilutamide in Patients with Metastatic Prostate Cancer who Underwent Orchiectomy: A Systematic Review and Metaanalysis
Current Clinical Pharmacology SPECT-CT and PET-CT in Oncology - An Overview
Current Medical Imaging Detection and Specific Targeting of Hypoxic Regions within Solid Tumors: Current Preclinical and Clinical Strategies
Current Medicinal Chemistry An Unbiased Predictive Model to Detect DNA Methylation Propensity of CpG Islands in the Human Genome
Current Bioinformatics Cytotoxic and Radio-sensitizing Effects of Polyphenolic Acetates in a Human Glioma Cell Line (BMG-1)
Current Pharmaceutical Design Application of a “Fit for Purpose” PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide
Drug Metabolism Letters Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics Castration-resistant Prostate Cancer: Novel Therapeutics Pre- or Post- Taxane Administration
Current Cancer Drug Targets 2D-Gel Electrophoresis Analysis of Proteomic Changes in Three Human Cell Lines; HEK 293, HepG2 and 1321N1 Cells in Response to Cadmium
Current Proteomics Recent Advances in Synthesis and Identification of Cyclic Peptides for Bioapplications
Current Topics in Medicinal Chemistry Human Galectin-3 Selective and High Affinity Inhibitors. Present State and Future Perspectives
Current Medicinal Chemistry Editorial [Hot topic: (Part I) Recent Trends in Anti-Cancer Drug Discovery (Guest Editor: Fazlul H. Sarkar)]
Mini-Reviews in Medicinal Chemistry Inhibiting the “Undruggable” RAS/Farnesyltransferase (FTase) Cancer Target by Manumycin-related Natural Products
Current Medicinal Chemistry Synthesis of Unsymmetrical C5-Curcuminoids as Potential Anticancer Agents
Letters in Drug Design & Discovery Tachykinins and their Receptors in Human Malignancies
Current Drug Targets Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies
Current Pharmaceutical Design The Apoptotic Pathway as a Therapeutic Target in Sepsis
Current Drug Targets Androgen Therapy in Male Patients Suffering from Type 2 Diabetes: A Review of Benefits and Risks
Current Diabetes Reviews